Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirolimus topical - OrphAI Therapeutics

Next Previous
X
Search
Drug Profile

Sirolimus topical - OrphAI Therapeutics

Alternative Names: LAM 004; Rapamycin topical - OrphAI Therapeutics

Latest Information Update: 04 Oct 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AI Therapeutics
  • Developer OrphAI Therapeutics
  • Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifibrotics; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibroma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Fibroma; Sarcoidosis; Skin disorders

Most Recent Events

  • 28 Sep 2023 AI Therapeutics is now called OrphAI Therapeutics
  • 21 Jun 2022 Discontinued - Phase-II for Fibroma in USA (Topical) before June 2022 (AI Therapeutics pipeline, June 2022)
  • 21 Jun 2022 Discontinued - Phase-II for Sarcoidosis in USA (Topical) before June 2022 (AI Therapeutics pipeline, June 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top